Experiment 66812
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Cynara scolymus (ASTERACEAE) |
| Citation | ENGLISCH,W: BECKERS,C: UNKAUF,M: RUEPP,M: ZINSERLING,V:. (2000). EFFICACY OF ARTICHOKE DRY EXTRACT IN PATIENTS WITH HYPERLIPOPROTENINEMIA.. 50(3) |
| Amount utilized | |
| Compound isolated | |
| Disease | EFFICACY AND TOLERABILITY OF ARTICHOKE DRY EXTRACT (DRUG/EXTRACT RATIO 25-34: 1, AQUOUS EXTRACT, CY450) AS COATED TABLETS CONTAINING 450 MG EXTRACT (TRADENAME: VALVERDE ARTISCHOCKE BEI VERDAUUNGSBECHWERDEN) WAS INVESTIGATED IN THE TREATMENT OF HYPERLIPOPROTEINEMIA AND COMPARED WITH PLACEBO. 143 ADULT PATIENTS WITH INITIAL TOTAL CHOLESTEROL OF > 7.3 MMOL/1 (<280 MG/D1) WERE INCLUDED IN A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CENTER CLINICAL TRIAL. PATIENTS RECEIVED 1, 800 MG ARTICHOKE DRY EXTRACT PER DAY OR PALCEBO OVER 6 WEEKS. CHANGES OF TOTAL CHOLESTEROL AND LDL-CHOLESTEROL FROM BASELINE TO THE END OF TREATMENT SHOWED A STATISTICALLY SIGNIFICANT SUPERIORITY (P=0.0001) ARTICHOKE DRY EXTRACT OVER PLACEBO. THE DECREASE OF TOTAL CHOLESTEROL IN THE CY450 WAS 18.5% COMPARED TO 8.6% IN THE PLACEBO GROUP. LDL-CHOLESTEROL DECREASE IN THE CY450 GROUP 22.9% AND 6.3% FOR PLACEBO. LDL/HDL RATIO SHOWED A DECREASE OF 20.2% IN THE CY450 GROUP AND 7.2% IN THE PLACEBO GROUP. THERE WERE NO DRUG RELATED ADVERSE EVENTS DURING THIS STUDY INDICATING AN EXCELLENT TOLERABILITY OF ARTICHOKE DRY EXTRACT. THIS PROSPECTIVE STUDY COULD CONTRIBUTE CLEAR EVIDENCE TO RECOMMEND ARTICHOKE DRY EXTRACT CY450 FOR TREATING HYPERLIPOPROTEINEMIA AND, THUS, PREVENTION OF ATHEROSCLEROSIS AND CORONARY HEART DISEASE. |
| Dose amount | 1.8 GM |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | H2O EXT |
| Gender | GIVEN TO BOTH SEXES |